By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sunovion Pharmaceuticals Inc. 

84 Waterford Drive

Marlborough  Massachusetts  01752  U.S.A.
Phone: 508-481-6700 Fax:



Acadia  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.


Company News
Sunovion Initiates SEP-363856 Phase II Program For Patients With Schizophrenia Or Parkinson’s Disease Psychosis 12/2/2016 7:44:28 AM
Demi Lovato, Sunovion And Leading Advocacy Organizations Launch The Be Vocal Collection In Partnership With Getty Images To Encourage The Realistic Portrayal Of Mental Health 11/30/2016 10:20:26 AM
Sunovion Recognizes Epilepsy And COPD Awareness Months In The U.S. During November 11/1/2016 12:30:16 PM
Sunovion Announces Positive Clinical Study Results For Latuda (Lurasidone HCL) In Adolescents With Schizophrenia 10/27/2016 11:29:40 AM
Sunovion Completes Acquisition Of Cynapsus (CYNA) 10/21/2016 8:25:35 AM
The American College of Chest Physicians And Sunovion Announce Strategic Initiative Focused On The Importance Of Drug Delivery In The Management Of COPD 10/20/2016 3:01:32 PM
Sunovion Announces FDA Filing Acceptance Of New Drug Application For SUN-101/Eflow For The Treatment Of Patients With Chronic Obstructive Pulmonary Disease (COPD) 10/13/2016 11:29:56 AM
Sunovion Announces Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Children With ADHD 9/20/2016 11:31:50 AM
Massachusetts' Sunovion Swallows Up Cynapsus (CYNA) in $624 Million Deal, Gains Experimental Parkinson's Drug 8/31/2016 3:48:27 PM
Sunovion Pharmaceuticals Inc. Hands On! Annual Community Service Program Contributes More Than 20,000 Employee Volunteer Hours Over Five Years To Support Youth Organizations And Community Relief Efforts 8/18/2016 10:54:27 AM